TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells

Table 1 Clinicopathological characteristics of 60 cases of NSCLC and TrkB expression by immunohistochemistry.

Clinicopathological charateristics	Cases (n = 60)	Higher exression (n = 40)	Lower expression (n = 20)	P value
Tumor size and invasiveness
T1+T2	40	27	13	0.846
T3+T4	20	13	7
Histological type
Sq	25	15	10	0.355
Ad	35	25	10
Differentiation
well-moderate	44	28	16	0.409
Poor	16	12	4
Stage
I+II	34	19	15	0.043*
III	26	21	5
Lymph node status
+	30	24	6	0.028**
-	30	16	14

TrkB expression: * = significant difference between early (I+II) and advanced (III) stage of NSCLCs; ** = significant difference between tumors with positive (+) and negative (-) nodes.

ISSN: 1471-2407